Brazil's Anvisa suspends specific statin and dexamethasone batches

The National Health Surveillance Agency (Anvisa) announced the suspension of commercialisation, distribution and use of several drug batches after safety concerns. Cimed voluntarily recalled batch 2424299 of atorvastatin 40 mg and rosuvastatin 20 mg because cartons of rosuvastatin were allegedly placed in packaging labelled for atorvastatin, creating a risk of patients receiving the wrong medication. Hypofarma also recalled batch 25091566 of fosfato dissódico de dexametasona 4 mg/ml injectable after detecting a turbid appearance when the solution was diluted, indicating possible contamination.

Both suspensions were published in the Diário Oficial da União on 18 May 2026 and apply nationwide. In the same decision, Anvisa prohibited the manufacturing, sale, import, advertising and use of a range of unregistered fitoterápicos, including products such as “Composto Cura Tudo” and the “Status Verde” line.

No adverse‑event reports have been released, but patients are advised to verify the batch numbers on their medication packaging and to seek guidance from pharmacists or physicians before continuing treatment.